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Full Guideline 
Scope and Purpose 
Background 
Sjögren’s syndrome is a chronic, immune-mediated, condition of unknown aetiology 
characterized by focal lymphocytic infiltration of exocrine glands (1).  Patients 
characteristically complain of drying of the eyes and mucosal surfaces along with fatigue 
and arthralgia. There is an association with autoimmune thyroid disease, coeliac disease and 
primary biliary cirrhosis. Systemic features include inflammatory arthritis, subacute lupus 
erythematosus, immune thrombocytopaenia, vasculitis with purpura, salivary gland 
inflammation, neuropathies, interstitial lung disease and a 5-10% lifetime risk of B-cell 
lymphoma (2, 3). This guideline reviews the treatment of the glandular and systemic 
features of primary Sjögren’s syndrome. The management of the glandular features includes 
conserving, replacing and stimulating secretions.  Systemic features may require system 
specific therapy and immunomodulatory treatment. Holistic management is important and 
many patients benefit from non-pharmacological therapies and general support. 
 
Diagnosis 
Patients commonly present with dryness of the eyes (4) and mouth (5).  In the early stages 
they may complain of grittiness rather than dryness of the eyes and the mouth symptoms 
may require prompting. Fatigue and arthralgia are almost universal. There is often a 
considerable delay between symptom onset and diagnosis. The most widely accepted 
current classification criteria for Primary Sjögren’s Syndrome and those referred to in this 
guideline are the American-European Consensus Group (AECG) criteria (6). The 2016 ACR-
EULAR criteria have just been published (7) derived from criteria proposed by the Sjögren’s 
International Collaborative Clinical Alliance (SICCA) (8). The population described by both 
criteria are very similar.   
For a definite diagnosis the AECG criteria require4 out of 6 of Dry eye symptoms, Dry mouth 
symptoms, Objective ocular dryness (Schirmer’s test < or = 5mm in 5 mins/van Bijsterveld 
score >=4) , Objective oral dryness (unstimulated salivary flow rate < or = 0.1ml/min or 
positive salivary scintigraphy and sialography), Positive Anti-Ro/La antibodies, Labial gland 
focus score > or =1  including at least one of the last two objective features.   
The 2016 ACR/EULAR classification criteria are based on the weighted sum of 5 items and 
require a total score > or =4 to meet the criteria for diagnosis where the presence of Anti-Ro 
antibodies or Focal lymphocytic sialadenitis with a focus score of > or =1 score 3 each and 
where abnormal ocular staining score > or =5, Schirmer’s test result of < or =5mm/5 minutes 
and unstimulated salivary flow rate of <0.1ml/minute score 1 each. 
Investigations 
The best-described autoantibodies in Primary Sjögren’s syndrome are the anti-Ro and anti-
La antibodies, which are routinely identified as part of the ENA (extractable nuclear antigen) 
laboratory screen. About two-thirds of patients with Primary Sjögren’s syndrome have anti-
Ro antibodies and/or anti-La antibodies. These figures, however, depend on the 
classification criteria used, referral bias and access to labial gland biopsy. 
 
Need for Guideline 
Primary Sjögren’s syndrome typically presents in women in their 5th or 6th decade, although 
up to 10% of cases occur in men and it is also seen in younger people. Studies using the 
AECG criteria have estimated the prevalence in women in the UK at 0.1-0.4% (9). Patients 
present to primary care physicians, general physicians, ophthalmologists and dental 
practitioners many of whom lack specialist knowledge regarding the treatment of this 
patient cohort. 
 
Objective of Guideline 
This document aims to provide a pragmatic, practical guideline for the management of 
adults with Primary Sjögren’s syndrome.  
 
Target audience 
The target audience includes Rheumatologists, General Physicians, General Practitioners, 
Specialist Nurses and other specialists (e.g. Ophthalmologists, Dental Practitioners and Ear, 
Nose and Throat Specialists) who will review patients with primary Sjögren’s syndrome 
during their clinical practice. The guideline should also be of relevance to Specialist 
Registrars in training and Specialist Nurses. 
 
Areas NOT covered 
The management of children with Sjögren’s syndrome is not specifically covered by this 
guideline although the general management of children and teenagers with Sjögren’s 
syndrome is similar to that for adults with special emphasis on the importance of good 
dental care and hygiene to preserve dental health. 
Sjögren’s syndrome is very rare in teenagers and there are only anecdotal reports world-
wide of its occurrence in pre-pubertal children so we would recommend that children and 
teenagers presenting with symptoms suggestive of Sjögren’s syndrome are referred to a 
specialist centre for evaluation and treatment.  
In addition this guideline does not cover the detailed management of patients with 
secondary Sjögren’s.  Where patients have secondary Sjögren’s syndrome their systemic 
management should address the primary disease but the advice on topical management 
contained in these guidelines is applicable to sicca symptoms from any cause. This guideline 
does not cover the detailed management of patients with lymphoma who should be 
managed in conjunction with oncologists and haematologists. 
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Rigor of Development & limitations 
A search was undertaken for all relevant evidence in the Cochrane Library, MEDLINE (Ovid & 
PubMed) and EMBASE from 1990 to current (February 2015 and updated September 2015). 
Additional references were added through regular updates to the draft recommendations 
up to January 2016. Non-English language papers were excluded unless a translation was 
published. We also excluded treatments not currently available in the United Kingdom 
unless there was a significant likelihood they would become available in the near future. 
Identified papers were reviewed, categorised, and the level of evidence graded according to 
international criteria from Ia through to IV and A through to B (10). See appendix 1 for full 
details of search criteria and Level of Evidence (LOE) definitions. 
The guideline was developed in line with the BSR Guideline Protocol using Appraisal of 
Guidelines for Research and Evaluation II (AGREE II) methodology 
(http://www.agreetrust.org/). The wording and content of the recommendations was 
subjected to a formal Delphi process (11) using on-line surveys to determine the eventual 
Strength of Agreement (SOA) for each recommendation. The Delphi method was developed 
in the 1950s. It describes a process whereby a group of experts anonymously reply to 
questionnaires and subsequently receive feedback in the form of a statistical representation 
of the group response, after which the process repeats itself. The goal is to reduce the range 
of responses and arrive at something closer to expert consensus. In our case each 
recommendation was rated on a score from 1 (no agreement) to 10 (complete agreement). 
The results were collated and circulated to the group prior to the second round. We then 
included recommendations with a mean Strength of Agreement (SOA) score of ≥7 plus >75% 
respondents scoring ≥7. This is expressed as the mean score with percentage ≥7 in brackets 
e.g SOA 7 (75%) with a maximum of 10 (100%). 
 
The Guideline 
Eligibility criteria 
This guideline is primarily aimed at the management of patients with Primary Sjögren’s 
Syndrome as defined by the AECG (6) or ACR-EULAR (in press) criteria but the advice on 
topical management contained in these guidelines is applicable to sicca symptoms from any 
cause. 
 
Exclusion criteria 
Sicca symptoms can result from a variety of causes, some of which may be reversible if 
addressed. Drugs are a common cause of sicca and many different drug groups have been 
implicated. Potential causative agents include those with anti-cholinergic activity such as 
anti-depressants, anxiolytics and anti-psychotics; muscarinic anatagonists such as 
tamsulosin hydrochloride and ipratropium hydrochloride; anti-histamines; opiates; anti-
hypertensives including Beta-blockers and ACE inhibitors; and proton pump inhibitors such 
as omeprazole. Avoiding these entirely may not be practicable but use should be minimised 
in the presence of sicca symptoms if possible.  
Sicca symptoms are commonly seen following head and neck radiotheraphy and may 
respond to topical treatment and pilocarpine (see below). Dehydration and acute anxiety 
may cause temporary sicca symptoms. Rarely, primary salivary gland pathology other than 
Sjögren’s syndrome including sarcoidosis, IgG4 disease (12) and graft versus host disease 
(13) may be implicated. Salivary gland aplasia and ductal atresia(14) are both rare causes of 
oral sicca and viral infections including Hepatitis C and HIV can cause salivary gland disease 
with hypertrophy and sicca symptoms.  
Xerostomia can be a feature of oral dysaesthesias with no objective reduction in salivary 
flow rate.  Oral dysaesthesia or burning mouth syndrome is a chronic pain condition 
currently classified as a neuropathic disorder. Such patients may complain of a constellation 
of oral symptoms, including burning sensations, unusual taste as well as oral dryness and 
their symptomatology is not uncommonly associated with anxiety states and clinical 
depression.   There may also be a history of low back pain, fibromyalgia and irritable bowel 
syndrome (15).  
A syndrome comprising histological evidence of sialadenitis, nodular osteoarthritis and 
xerostomia (SNOX) has been described (16) but in view of the frequency of the individual 
clinical features and the demographics of the individuals with these conditions, clustering of 
these entities could also be expected to occur on a simple statistical basis.  
Ageing per se is not a cause of xerostomia.  Although there is a broadly linear reduction in 
the amount of functional acinar tissue within the salivary glands over time, this does not 
lead to clinically significant salivary gland hypofunction in normal subjects (17). Xerostomia 
in the ageing population is more a function of intercurrent disease and medication rather 
than loss of secretory ability (18). 
 
The Guideline 
The guideline covers management of the eye and mouth manifestations, systemic dryness 
and systemic disease in general with comments on the management of pregnancy and 
lymphoma in patients with Sjögren’s syndrome. For each section we have reviewed and 
summarised the available evidence and then list the recommendations which achieved a 
mean SOA score of >7 plus 75% of respondents scoring > 7 after the 2nd round of the Delphi 
process as described above. In general we would recommend initial symptomatic treatment 
of sicca manifestations combined, if appropriate, with systemic management. 
 
Treatment of Sicca manifestations 
All patients with Primary Sjögren’s Syndrome (and sicca from other causes) should be 
offered symptomatic treatment of dryness. The sicca symptoms classically affect eyes and 
mouth but many patients also experience a chronic, dry cough due to drying of the mucosal 
surfaces and, in women, vaginal dryness. In general treatment of sicca symptoms should aim 
to conserve, replace and stimulate secretions whilst reducing inflammation. 
 
Management of Ocular manifestations of Sjögren’s syndrome 
Dry eyes may be classified as mild, moderate or severe based on the presence of both 
symptoms and signs (19). Definitions are included in Table 1 and rely on knowing the Tear 
film break up time and/or the Ocular surface staining score. In the past, staging of eye 
disease has not routinely been carried out by optomoterists and ophthalmologists but this is 
changing with routine staging being introduced for other eye diseases. In practice 
Rheumaamtologists and GPs will either rely on patient reported symptoms or simple 
Schirmer’s testing to assess severity of disease but, by definition the majority of patients 
with Sjögren’s syndrome will have severe dry eye (Schirmer’s < or = 5mm in 5 minutes and 
Tear Break up Time < or = 5 seconds). 
It should be remembered that in Sjögren’s associated dry eye all 3 layers of the tear film are 
affected. There is mucosal layer deficiency, aqueous deficiency and meibomian gland 
deficiency all of which need to be addressed. 
 
Ocular – Conservation of Tears and meibomian gland secretions 
Systemic medications that exacerbate dryness should be avoided if possible. These include 
those with anti-cholinergic activity (psychotropics including antidepressants, anxiolytics and 
anti-psychotics), muscarinic antagonists (e.g. tamsolusin hydrochloride; ipratropium 
hydrochloride), anti-histamines, opiates, anti-hypertensives (e.g. Beta blockers; ACE 
inhibitors) and proton pump inhibitors (e.g. omeprazole) althought the latter may have an 
important role in the treatment of layngotracheal reflux.  
Studies have shown that humidification of cabin air increases tear-film stability (20) in 
normal individuals and by extrapolation it is advised for dry eye. Patients consistently report 
feeling more comfortable in a humidified environment.  
Two randomised placebo controlled trials showed improvements in symptoms of dry eye 
following oral supplementation with Omega 3 fatty acids, with improvement in both 
Schirmer’s test and markers of ocular inflammation (21, 22). There is some low quality 
evidence that Omega 7 derived from Sea Buckthorn Oil provides some symptomatic relief of 
dry eye symptoms from both a small, open label, informal study (23)  and a double-masked, 
randomised, parallel trial (25). The evidence was felt to be of insufficient strength to include 
this as a recommendation within the final guideline.  
Adequate meibomian gland secretion is essential to prevent evaporative tear loss. There is 
evidence that it is useful to enhance meibomian gland secretion using either warm 
compresses or commercially available eye bags or other devices (26). Patients should be 
advised to perform lid hygiene if required using proprietary wipes (available over the 
counter) or with a weak solution of bicarbonate. Useful guides for patients are available on 
both the NHS and NICE websites (27, 28)  
A recent report by the American Academy of Ophthalmologists reviewed the evidence for 
the oral antibiotics doxycycline, minocycline, and azithromycin in the management of ocular 
surface disease arising from disorders of the meibomian glands. They identified 8 studies 
which documented an improvement in meibomian gland-related ocular surface disease 
after treatment with these agents, although side effects were common. Only one study was 
a randomized, controlled trial. They concluded oral antibiotics may be an effective 
treatment for ocular surface disease that results from meibomian gland disease (29). Two 
small observational, open label clinical studies of topical azithromycin ophthalmic solution 
1% (twice daily for 2 days and once daily on days 3-28) in subjects with symptomatic 
Meibomian Gland Disease, but not specifically Sjögren’s syndrome, showed improvement in 
both clinical signs and symptoms of disease (30, 31). Expert advice in the UK is to consider 
doxycycline 50mg od for a minimum of 3 months in patients with persistent meibomian 
gland inflammation and blepharitis not responding to topical management. If treating young 
patients it is important to remember that doxycycline is contraindicated in those less than 
12 years of age.  Minocycline is avoided because of the small risk of causing drug-induced 
lupus. 
Wearing spectacles reduces surface evaporation of tears by up to 30% and the effect can be 
optimised by the use of moisture chamber spectacles (32, 33). The latter can be 
manufactured by opticians or purchased on-line. There is evidence supporting the early use 
of punctal plugs (34, 35) which improve symptoms of dry eye significantly more than 
artificial tears alone.  
First line treatment should be with visible plugs. If this successfully improves symptoms or 
signs, and there is no evidence of excess watering or over flow of tears, then permanent 
punctal occlusion can be achieved with punctal cautery. Intracanalicular plugs are effective 
but increase the risk of granuloma and infection (36, 37) and are not visible on examination . 
Referral to an ophthalmologist is advised and it is important to remember that plugs are 
available in different sizes and the puncta should ideally be measured with a calliper prior to 
selection and insertion of an appropriately sized plug. Improperly sized plugs may fall out, 
with accompanying deterioration in symptoms; alternatively loose plugs will allow tear flow, 
or cause irritation.  
 
Recommendations for Conservation of Tears and meibomian gland secretions  
I. Treatment should begin with conservation of tears by humidification and avoidance 
of systemic medication that exacerbates dryness. Level of evidence Ib/A; SOA 8.9 
(97%) 
II. Patients should be advised to stimulate meibomian gland secretion daily using either 
warm compresses or commercially available eye bags or other devices and perform 
lid hygiene if required using proprietary wipes (available over the counter) or with a 
weak solution of bicarbonate. Level of evidence III/C; SOA 8.9 (93.3%) 
III. In patients with persistent meibomian gland inflammation and blepharitis treatment 
with doxycycline 50mg od for a minimum of 3 months may be effective.  Level of 
evidence IV/D; SOA8.83 (92.9%) 
IV. Early referral to an ophthalmologist for review and consideration of insertion of 
punctal plugs or cauterisation of puncta is recommended. Level of evidence II/B; SOA 
9.27 (100%) 
 
Ocular – Replacement of Tears and Meibomian Gland Secretions 
Liposomal sprays (available over the counter but not currently FP10 prescribable) reduce 
evaporative tear loss and replace the meibomian gland layer and have been shown to 
significantly reduce sicca symptoms (38).  
To replace the aqueous tear film start with simple lubricating drops using the most cost-
effective options. In general start with low viscosity simple drops such as hypromellose and 
escalate as symptoms dictate. Given the severity of dry eye disease in primary Sjögren’s 
syndrome, it is unlikely however that simple drops will be sufficient to control the disease. 
When prescribing take in to account the bottle or device used to apply the drops. In 
particular consider ease of application and expiry dates. See advice below and in 
accompanying Table 21 for preparations.  
Multi-use ophthalmic preparations rapidly become colonised with bacteria and are 
associated with high rates of pathogenic organisms on conjunctival culture(39). As a result, 
the majority of multi-dose preparations contain a preservative to limit bacterial, fungal and 
amoebic ocular infections and prolong shelf life by preventing biodegradation.  High 
concentrations of certain preservatives may damage and irritate ocular tissue and this effect 
is enhanced in those with ocular surface disease. Benzalkonium Chloride (BAK) is the most 
frequently used preservative in topical ophthalmic preparations and its epithelial toxic 
effects are well established (40). Preserved preparations should be avoided in patients using 
eye drops long term (for > 3 months), instilling drops more than 4 times daily or those with 
ocular surface disease (effectively the majority of patients with Primary Sjögren’s 
Syndrome). Some eye drops are available as single-use preservative free preparations. 
Although convenient these are often costly and require good manual dexterity to use. 
Increasingly eye drops are available in multi-use bottles with preservative systems that 
either biodegrade on contact with light or with the ocular surface. Other preservative free 
multidose systems use a pump or vacuum system preventing regurgitation into the bottle 
and obviating the need for preservatives altogether.  
 Autologous or allogeneic serum eye drops are the only available nutritional tear substitutes 
and are effective and well tolerated by patients (41, 42). However they are very expensive 
to produce and are only available from commissioned specialist centres.  
 
Recommendations for Replacement of Tears and Meibomian Gland  
I. Recommend liposomal sprays to reduce evaporative tear loss and replace the 
meibomian gland layer Level of evidence III/C; SOA 8.29 (92.8%) 
II. Start with simple lubricating drops using the most cost-effective options (see Table 
21 for preparations) Level of evidence IV/D; SOA 9.3 (93.3%) 
III. Avoid preservative containing preparations Level of evidence I/A; SOA 9.21 (92.9%) 
IV. Patients with severe dry eye, not responding to conventional treatment may be 
referred to specialist centres for consideration of autologous or allogeneic serum eye 
drops. Level of evidence IIb/B; SOA 9.5 (100%) 
 
Ocular – anti-inflammatory 
There is evidence supporting the use of topical anti-inflammatories under ophthalmic 
supervision in patients with persistent corneal inflammation. Low dose steroid containing 
eye drops are recommended for short term use and have been shown to be both safe and 
effective (43). Longer term use of topical steroids has been associated with an increased risk 
of glaucoma and cataract and should be avoided(44). In general the use of topical steroids 
should be limited to patients under supervision by an ophthalmologist. For longer term use 
ciclosporin containing eye drops have been shown to reduce subjective symptoms and 
improve objective signs of inflammation in patients with both primary and secondary 
Sjögren’s syndrome (45-47). Ciclosporin 0.1% (Ikervis®) is licensed and NICE approved as a 
possible treatment for people with dry eye disease that has not improved despite treatment 
with artificial tears (NICE TAG 369 December 2015 (48)) but must initially be prescribed by a 
sub-specialty ophthalmologist. An unlicensed veterinary ointment (Optimmune®, 
Ciclosporin 0.2%) or a preservative free eye drop available via Moorfields Pharmaceuticals 
may be used as alternatives. All forms of topical ciclosporin may be used off license for 
patients <16 years of age. 
 
Topical NSAIDs such as diclofenac and indomethacin have been shown to improve ocular 
discomfort but reduce corneal sensitivity and may predispose to further corneal damage 
and should therefore be used only with caution in patients with Sjögren’s syndrome (49, 
50). 
 
Recommendation for anti-inflammatory treatment of dry eye 
I. Low dose steroid containing eye drops are recommended for short term use under 
ophthalmic supervision only Level of evidence Ib/A; SOA 9.64 (100%) 
II. Longer term use of topical steroids should be avoided Level of evidence Ib/A; SOA 
9.64 (100%) 
III. Ciclosporin containing eye drops or ointments may be used under ophthalmic 
supervision in patients with evidence of chronic inflammation Level of evidence Ib/A; 
SOA 9.38 (100%) 
IV. Topical NSAIDs such as Diclofenac and indomethacin should be used with caution 
under ophthalmic supervision only Level of evidence IIb/B; SOA 9.86 (100%) 
 
Ocular - Stimulate 
Oral pilocarpine treatment can improve ocular dryness and tear film break up time and 
increase goblet cell density thus improving the mucous layer (51-55). Symptomatic and 
objective improvements are seen in more than a third of patients although side effects 
(headache, increased sweating) may limit its use in some.  
The recommended starting dose is 5 mg once daily, escalating at weekly intervals as 
tolerated to 5mg qds (with meals and at bedtime) but if response is insufficient, the dose 
can be increased to 30 mg daily, if tolerated well; discontinue if no improvement after 2–3 
months. Contra-indications include uncontrolled asthma and Chronic Obstructive Pulmonary 
Disease, uncontrolled Cardiorenal disease and acute iritis. Common side effects include 
dyspepsia, diarrhoea, abdominal pain, flushing and increased urinary frequency. There is 
evidence from an observational study that it is both safe and effective in children and young 
people as young as 9 years of age (56). In patients intolerant of pilocarpine tablets, using 
topical ocular drops orally allows delivery of a smaller dose of drug and may be better 
tolerated. The Palliative drug formulary suggests 2-3 drops of pilocarpine 4% eye drops is 
equivalent to 4-6mg oral pilocarpine, however this is an off-licence use (57) 
 
Recommendations for Stimulation of ocular secretions 
I. A trial of Pilocarpine 5mg once daily increasing stepwise to 5mg qds is recommended 
for patients with significant sicca symptoms and no contraindications to its use. Level 
of evidence IIb/B; SOA 9.08 (92.3%) 
 
Miscellaneous treatments for Dry Eye and Ocular complications 
Mucolytic eye drops, e.g. Acetylcysteine 5-10% non-preserved, are useful for patients with 
mucous threads or ocular surface filaments (58) and have also been shown to improve Tear 
Break Up time and Schirmer’s tests in patients with Meibomian Gland disease (59). 
Some patients with severe dry eye develop an associated blepharospasm. There are small 
case series describing a good response to Botulinum toxin injections in these circumstances 
(60, 61). 
For severe dry eye Bandage scleral contact lenses, designed to protect the surface and 
create an optimised environment for healing may be indicated. These lenses vault over the 
corneal surface and rest on the sclera. They are rigid and gas-permeable and require 
specialist fitting and manufacture. They are only available in specialist centres for severe 
corneal disease refractory to other treatment measures. A number of studies have shown 
significant decreases in corneal staining with Scleral Contact Lens wear with significant 
improvements in dry eye symptoms and quality of life (62-64). 
Corneal grafting or amniotic membrane overlay may occasionally be indicated for cases of 
significant corneal ulceration and corneal melt (65). Neuropathic pain (when dry eye 
symptoms outweigh clinical findings) is a recognised entity). Neuropathic pain strategies 
should be considered for these patients (66).  
 
Recommendations for severe, complicated dry eyes 
I. Mucolytic eye drops should be prescribed for patients with mucous threads or ocular 
surface filaments Level of evidence III/C; SOA 9.38 (100%) 
II. Patients with severe dry eye and associated blepharospasm may benefit from 
referral to a specialist centre for consideration of Botulinum toxin treatment Level of 
evidence III/C; SOA 9.17 (100%) 
III. Patients with severe dry eye and corneal ulceration, not responding to conventional 
treatment, may be referred to specialist centres for consideration of ‘bandage’ 
contact lenses or amniotic membrane grafting or corneal grafting for perforations 
Level of evidence III/C; SOA 9.15 (92.9%) 
 
Management of Oral Manifestations of Sjögren’s syndrome 
Dry mouth (xerostomia) is a hallmark of primary Sjögren’s syndrome and the majority of 
patients suffer from both reduced salivary flow rate and increased viscosity of saliva due to 
relative deficiency of the aqueous component, which may compromise oral health.   
Complications of long-term xerostomia include oral discomfort and soreness and a burning 
sensation in the mouth. An increased rate of dental caries, excessive tooth wear and 
premature tooth loss are often observed. Patients struggle to achieve a high standard of 
oral hygiene and may suffer from halitosis. Patients tolerate dentures poorly and often 
complain of difficult retaining them in the mouth with sore, ulcerated gums as a 
consequence of rubbing. Many patients suffer recurrent infections including parotitis, 
intraoral candidiasis and angular cheilitis. Dysarthria, dysphagia and dysgeusia (distorted 
sense of taste) are seen in established disease.     
The evidence surrounding periodontal disease in Sjögren’s is conflicting with some studies 
suggesting an increased prevalence of periodontal disease (67) but others not (68).  
Effective management of the dry mouth is important for the maintenance of oral health and 
to improve oral health-related quality of life (OH-QoL) as well as general health and quality 
of life. 
 
Oral – conserve 
Many patients with primary Sjögren’s syndrome anecdotally report improvement in 
symptoms following humidification of room air and patients frequently report worsening of 
symptoms in dry and air-conditioned environments.  
Patients with primary Sjögren’s syndrome have higher rates of the cariogenic bacteria 
streptococcus mutans, dental caries and dental loss compared to controls despite 
apparently good dental care (69, 70). Dental caries is considered to be a diet-mediated 
disease, as sugars are essential in the caries process. This has been confirmed in several 
large population based studies which have shown a significant association between total 
sugar intake and the development of dental decay over time in a normal population. Twice 
daily use of fluoride toothpaste reduced but did not eliminate the association between diet 
and dental decay in these studies (71-73). 
Given their enhanced risk of dental decay patients with primary Sjögren’s syndrome should 
be advised to practice excellent oral hygiene and avoid sweetened food and drink on a 
regular basis. Assessment by an Oral Medicine specialist and/or regular visits to a general 
dental practitioner are recommended to monitor and treat the oral manifestations of 
Sjögren’s syndrome with the emphasis on preventative dental care.  
The optimum concentration of fluoride in standard toothpaste has been calculated 
assuming a normal salivary flow rate and taking into consideration the availability of fluoride 
in normal saliva.  Concentrations of fluoride in ‘standard’ over the counter toothpastes vary 
from 500 parts per million (ppm) to 1000ppm and occasionally higher. ‘Prescription’ 
toothpastes contain fluoride concentrations of between 2800 and 5000 ppm. Dry mouth 
patients will need a higher concentration of fluoride in toothpaste to compensate for the 
lack of salivary fluoride. A number of studies (74-76) and a Cochrane review (77) have 
concluded that caries protection is increased with higher fluoride concentrations. A 
systematic review of the literature and a Delphi consensus exercise by a national panel of 
experts in North America concluded that there was good evidence that  a prescription 
strength, home-use, fluoride gel or paste should be used in all patients with primary 
Sjögren’s syndrome (78).    
Acidic products and those containing sugar should not be prescribed for dentate patients 
since maintaining a neutral oral pH environment may reduce the development of dental 
caries (79). 
There is evidence that in addition to the total sugar content of the diet, frequency of sugar 
intake is implicated in dental decay (78). In light of this we recommend that patients with 
primary Sjögren’s syndrome avoid food and drinks other than plain water between meals 
and from 1 hour before bedtime and all through the night. 
Patients should be advised to brush their teeth at least twice daily (but not immediately 
after eating) including before bed at night using a pea sized amount of high fluoride 
toothpaste and use fluoride containing tooth mousse or gel on teeth twice daily. They 
should avoid alcohol containing mouth washes, sugary or fizzy drinks and frequent snacking 
(78) 
Chlorhexidine  is an effective antiseptic which inhibits plaque formation on teeth and is 
useful for controlling gingivitis (80). Many oral specialists and dentists recommend an 
alcohol free chlorhexidine mouth wash in primary Sjögren’s syndrome patients as 
preventative treatment for gum disease. It can be used twice daily for a maximum of 2 
weeks every 3 months but over use can lead to staining of teeth.  
 
Recommendations for conservation of moisture and oral hygiene  
I. Patients should be advised to humidify the environment Level of evidence IIV/D; SOA 
9.13 (100%) 
II. Patients should be advised to practice excellent oral hygiene, limit sugar intake and 
avoid food and drinks other than plain water between meals and from 1 hour before 
bedtime and all through the night Level of evidence IV/D; SOA 9.8 (100%) 
III. Assessment by an Oral Medicine specialist and/or regular visits to a general dental 
practitioner typically at 3 to 6 monthly intervals are recommended to monitor and 
treat the oral manifestations of Sjögren’s syndrome Level of evidence IV/D; SOA 9.8 
(100%) 
IV. Aim to avoid acidic products and those containing sugar when prescribing for 
dentate patients. Level of evidence IV/D SOA 9.87 (100%) 
V. Patients should be advised to brush teeth at least twice daily (but not immediately 
after eating) including before bed at night using a pea sized amount of high fluoride 
toothpaste and use fluoride containing oral mousse or gel on teeth twice daily Level 
of evidence I/A; SOA 9.8 (100%) 
VI. Alcohol free chlorhexidine mouth wash used twice daily for maximum of 2 weeks 
every 3 months can help prevent gum disease but over use can lead to staining of 
teeth Level of evidence IV/D; SOA 9.0 (100%) 
 
Oral - Replace 
It is common practice to manage mild symptoms by recommending that patients sip water, 
suck ice or chew sugar-free gum (78, 81). More severe dryness can be managed with 
commercially available topical and systemic treatments for dry mouth.  
Saliva substitutes provide symptomatic momentary relief of oral dryness. A Cochrane review 
of the effectiveness of topical treatments for dry mouth from any cause, including parallel 
and crossover randomised controlled trials of lozenges, sprays, mouth rinses, gels, oils, 
chewing gum and toothpastes did not find strong evidence for their effectiveness (82, 83) 
but in the experience of the working group patients report increased oral comfort from their 
use. 
The ideal preparation will have neutral pH and contain fluoride and other electrolytes, 
mimicking the composition of natural saliva. Saliva substitutes are available commercially in 
the form of oral sprays, gels and rinses. Most are freely available over the counter and some 
are prescription only. The choice will depend upon patient preference and local availability. 
Fluoride containing, neutral pH preparations should be prescribed for dentate patients (see 
appendix 2 for products available in the UK). Preparations with acidic pH and/or without 
added fluoride should only be used in edentulous patients  
There is limited evidence that an Oxygenated glycerol triester (OGT) saliva substitute spray 
is more effective than a water based electrolyte spray in older patients with dry mouth (84). 
Patients with Sjögren’s are at increased risk of frictional oral ulcers(85). There is evidence 
that Polyvinylpyrrolidone and sodium hyaluronate oral gel (Gelclair) may be helpful in 
patients with recurrent oral ulceration post chemotherapy but no published studies of its 
effectiveness in Sjögren’s syndrome (86).  A list of commercially available oral preparations 
is provided for reference in appendix 2. 
 
Recommendations for replacement of oral secretions 
I. Patients should be advised to use a neutral pH fluoride containing mouth wash, gel 
or spray as required for symptomatic relief.  Level of evidence III/C; SOA 9.43 (92.8%) 
 
Oral - Stimulate 
Topical Saliva Stimulants 
Although no study directly links improved salivary flow to caries prevention expert opinion 
acknowledges that increasing saliva flow is likely to reduce caries incidence in the longer 
term.  
Chewing sugar free gum increases saliva production and there is some evidence that in 
addition to its value as a non-sugar sweetener Xylitol may have a role in caries prevention in 
its own right  (87, 88). A recent Cochrane review of the evidence for xylitol concluded that 
over 2.5 to 3 years of use, a fluoride toothpaste containing 10% xylitol may reduce caries by 
13% when compared to a fluoride-only toothpaste but that there was insufficient evidence 
to determine whether any other xylitol-containing products could prevent caries in infants, 
older children, or adults (89). 
Many patients chew or suck sugar-free sweets and report benefit but there is no published 
evidence supporting this. Certain foodstuffs may be more effective at stimulating saliva than 
others but acidic products and those containing sugar should be avoided because of their 
cariogenic potential.  A small cross-over study in normal volunteers assessed the efficacy of 
yogurt and lemon juice as salivary stimulants and found that both were effective but yogurt 
more so than lemon juice compared to baseline leading them to suggest that yogurt is a 
potential candidate for the treatment of dry mouth and warrants further study (90). 
Some commercially available salivary stimulants are available in the UK. There is little 
convincing evidence of efficacy and conflicting results from the few reported studies (91, 
92). Preparations are listed in Appendix 3 for reference. 
A small single-blinded, open-label, cross-over clinical study of a branded dry mouth product 
(Xerostom) containing olive oil, betaine and xylitol in a population with polypharmacy-
induced xerostomia resulted in increased unstimulated whole salivary flow rates, reduced 
complaints of xerostomia and improved xerostomia-associated quality of life. No clinically 
significant adverse events were observed (93). The preparation is non-acidic and contains 
both fluoride and calcium so may be suitable for patients with Sjögren’s syndrome although 
there are no published studies in this patient population.  
Anhydrous crystalline maltose (ACM) is available over the counter or on-line and has been 
shown to increase salivary flow rates with minimal adverse effects in small, observational 
studies (94) but is not available on prescription.  
There is some experimental evidence for both acupuncture and mild electrical stimulation 
improving salivary flow rates. Published studies are generally small,  usually observational 
and are not specifically looking at patients with Sjogren’s syndrome (82). There were 
adverse effects reported with the use of acupuncture but these were mild and of short 
duration. There were no reported adverse effects from electro stimulation with some 
evidence for improved salivary flow and further, larger studies are planned but neither are  
currently routinely available in the UK for the treatment of sicca (95). A gel-releasing device 
(reservoir) worn in the mouth has been trialled and may be effective in some patients (96) 
but more research is needed.  
 
Recommendations for mechanical stimulation of oral secretions 
I. Patients should be advised to chew xylitol containing sugar free gum. Level of 
evidence III/C; SOA 9.67 (100%) 
 
Systemic stimulants 
Pilocarpine Hydrochloride (salagen) is licensed for use in the UK for dry mouth and eyes in 
Sjögren’s syndrome. It acts as an agonist on muscarinic-cholinergic receptors to stimulate 
secretion. It is effective in both primary and secondary Sjögren’s syndrome. There are a 
number of randomised, controlled trials in patients with Sjögren’s confirming significant 
symptomatic improvement and objective evidence of increased salivary flow in patients 
treated with pilocarpine (97-99). Evidence suggests that at least half of patients respond 
although it can take up to 12 weeks to see a therapeutic benefit. In long term use levels of 
candida colonisation reduce (100). Side effects are common and dose dependent. They 
include sweating, palpitations and flushing. See Ocular – stimulate section for more detail 
on the use of pilocarpine and adverse effects. 
Cevimeline is another muscarinic agonist that stimulates fluid secretion generally (101, 102) 
but has higher affinity for muscarinic receptors located on lacrimal and salivary gland 
epithelium and may be associated with fewer side effects compared with pilocarpine (103).  
However, this drug is not currently licenced for use in the UK.  
There is some limited evidence that the H2 blocker nizatadine mildly improves (20% over 
baseline) objective and subjective measure of oral dryness and is well tolerated although it 
is not licensed for this indication in the UK (104). 
 
Recommendations for systemic stimulation of secretions  
I. A trial of Pilocarpine 5mg once daily increasing stepwise to 5mg qds is recommended 
for patients with significant sicca symptoms and no contraindications to its use. Level 
of evidence IIb/B; SOA 9.77 (100%) 
 
Treatment of oral Candida 
Oral candida is a frequent problem in patients with Sjögren’s associated dry mouth (105) 
and patients have high levels of candida carriage despite good dental hygiene (106). 
Patients may have visible white plaques (simple infection) or erythematous infection, when 
they present with a red, raw tongue or oral cavity. Clinical experience suggests that whereas 
topical agents such as nystatin may be adequate to treat simple infection, oral fluconazole is 
required to treat erythematous infection. The presence of dentures creates an environment 
where candida may become persistent. 
Angular cheilits, where patients present with dry, fissured erythematous lesions in the 
corner of their mouths, is another manifestation of candidal infection in Sjögren’s 
syndrome. It can be effectively treated with miconazole topically for 2 weeks, using a clean 
cotton bud to apply to each side to prevent cross-contamination and persistence of 
infection (107).  
 
Recommendations for treatment of oral candida  
I. In simple candida infection (visible white plaques) treat with oral nystatin liquid 1ml 
five times daily for 7 days. Consider repeating the treatment for 1 week every 8 
weeks if frequent recurrence. If the patient has erythematous infection manifesting 
as a red, raw tongue or oral cavity & commonly seen in denture wearers, use 
fluconazole 50mg od for 10 days. Level of evidence IV/D; SOA 9.86 (100%) 
II. Treat angular cheilitis with miconazole topically for 2 weeks, using a clean cotton 
bud to apply to each side to prevent cross-contamination and persistence of 
infection. Level of evidence IV/D; SOA 9.86 (100%) 
 
Management of Salivary Gland enlargement 
Some patients with Primary Sjögren’s syndrome have recurrent or persistent salivary gland 
enlargement. This may occur during disease activity ‘flares’ or may reflect duct obstruction 
due to strictures, stones or inspissated secretions. 
Parotid sialography is a very specific diagnostic test for Primary Sjögren’s syndrome (108) 
which involves injection of contrast materials into the salivary ducts and is associated with a 
small risk of infection, ductal perforation and allergic reactions. Intraductal injection of 
contrast can assess the ductal system and exclude strictures (109). Interventional 
sialoendoscopy has been reported to be useful in patients with Sjögren's syndrome with 
chronic obstructive sialadenitis unresponsive to medical therapy. Under local anaesthesia 
the orifice of the salivary gland is intubated and the scope advanced, with continuous saline 
lavage. This allows obstructing plaques to be washed out and any strictures dilated. 
Symptomatic improvement was achieved in 85% of patients using this technique (110). 
However sialoendoscopy is not widely available and no large scale or long term studies have 
been published. 
In contrast salivary gland ultrasound (US) is non-invasive, well tolerated by patients and 
easily repeatable. Ultrasound allows assessment of the architecture of the major salivary 
glands and, used in conjunction with Doppler signals, it may help differentiate between 
benign and malignant lesions. In some centres salivary gland US is utilised as a diagnostic 
screening tool  and studies confirm it has a high positive predictive value of 85% with good 
correlation between abnormalities on US and salivary gland histology (111). Baseline 
ultrasound is recommended in patients with salivary gland swelling to look for active 
inflammation, infection and stones. Consider repeating the US if there is a history of new 
persistent or recurrent SG swelling to monitor for disease progression and development of 
complications (112).  
If there is acute inflammation in the absence of infection and stones then a short course of 
oral prednisolone or an intra-muscular injection of Depomedrone (typically 120mg) will 
often settle the glandular swelling promptly (anecdotal evidence). There is anecdotal 
evidence that massaging the glands can help reduce discomfort in chronically inflamed 
glands. 
 
Recommendations for management of salivary gland enlargement  
I. Consider salivary gland ultrasound to look for active inflammation, infection and 
stones. Level of evidence IV/D; SOA 9.7 (100%) 
II. If acute inflammation in the absence of infection and stones then a short course of 
oral prednisolone or an intra-muscular injection of Depomedrone will often settle 
the glandular swelling. Level of evidence IV/D; SOA 9.01 (100%) 
III. Massaging the glands can help reduce discomfort in chronically inflamed glands 
Level of evidence IV/D; SOA 9.31 (92.8%) 
 
Systemic dryness 
Many patients report a chronic dry cough due to drying of mucosal surfaces. Humidification 
of inspired air is reported to help by some patients(113). Pilocarpine improves secretions in 
general and anecdotally reduces the frequency and severity of dry cough.  A mucolytic agent 
(i.e. carbocysteine) reduced the viscosity of sputum, improved the ability to cough up 
bronchial secretions, reduced cough frequency and shortness of breath in a double blind 
controlled study of patients with chronic bronchitis (114). There is anecdotal evidence it 
helps in patients with Sjögren’s syndrome and an associated chronic, dry cough. 
Concomitant use of oral acetylcysteine with azathioprine and steroids should be avoided 
given evidence of increased hospitalisation and death in a group of patients with pulmonary 
fibrosis (but not Sjögren’s) treated with triple therapy versus placebo (115). It should be 
remembered that chronic dry persistent cough may be a sign of interstitial lung disease and 
should prompt appropriate investigations. 
Females with Sjögren’s syndrome frequently complain of vaginal dryness (116). Pilocarpine 
may help this by non-specifically stimulating secretions. There is evidence supporting the 
use of non-hormonal moisturisers in the treatment of vaginal dryness from any cause (117-
119). A number of products are available over the counter and are listed in appendix 3. 
Vaginal moisturizers applied on a regular basis have an efficacy equivalent to local hormone 
replacement for the treatment of local urogenital symptoms such as vaginal itching, 
irritation and dyspareunia (117). Patients with Sjögren’s syndrome have both vaginal 
dryness and atrophy of the genital skin (120). There is evidence supporting the use of topical 
oestrogen containing products in patients with post-menopausal vaginal atrophy and 
dryness (117). Creams and pessaries are equally effective and although systemic absorption 
can occur with local preparations there is no current evidence of an increased risk of 
endometrial thickening (117). The use of local hormone replacement therapy can reduce 
the frequency of recurrent urinary tract infections in post-menopausal women (117).   
 
Recommendations for management of systemic 
I. A trial of Pilocarpine 5mg once daily increasing stepwise to 5mg qds is recommended 
for all patients with significant systemic dryness and no contraindications to its use. 
Level of evidence IV/D; SOA 9.08 (92.3%) 
II. Patients with vaginal dryness should be advised to use a non-hormonal vaginal 
moisturiser with or without a topical oestrogen containing product. Level of evidence 
I/A; SOA 9.8 (100%) 
 
Treatment of Systemic Disease 
Systemic (extra-glandular) features are seen in approximately 70% of patients with Sjögren’s 
syndrome and are severe in about 15% (121). The most commonly involved organs are 
joints, lungs, skin and peripheral nerves (3). Raynaud’s and thyroid disease tend to be 
commoner in females and lung involvement and peripheral neuropathies are commoner in 
those with a disease duration of more than 10 years (2). Other systemic features may 
include autoimmune liver disease, renal involvement, Subacute Cutaneous Lupus (SCLE), 
Immune thrombocytopaenia (ITP), myositis, monoclonal gammopathy of uncertain 
significance (MGUS) and lymphoma. There are also common overlapping conditions, most 
notably thyroid disease in up to 20% (122), primary biliary cirrhosis in 8% (123) and coeliac 
disease in 4.5% (124). 
Although significant systemic complications are more common in the Ro/La positive group 
(3) recent evidence suggests that systemic complications also affect a reasonable proportion 
of the antibody negative group with Sjögren’s syndrome (125) suggesting that all patients 
with Sjögren’s syndrome warrant consideration of active treatment. 
 
Non-pharmacological interventions for systemic disease 
A recent systematic review evaluated the evidence for non-pharmacological interventions 
for primary Sjögren’s syndrome and found that much of the evidence was inconclusive 
(126). The available studies suggest that patients with Sjögren’s syndrome benefit from 
moderate to high intensity exercise with improvements in aerobic capacity, fatigue scores, 
physical functioning and depression (127). 
Lifestyle management strategies may benefit Sjögren’s syndrome patients if fatigue is 
significantly affecting their ability to perform daily activities. Strategies recommended by 
NICE guidance for fatigue include sleep management, activity management, relaxation 
techniques, cognitive behavioural therapy and graded exercise therapy. See relevant NICE 
guidance on management of fatigue in adults.  
Many patients report benefit from joining a Sjögren’s support group. The British Sjögren’s 
Syndrome Association provides information and advice for members via their website, a 
quarterly magazine and a dedicated telephone helpline (www.bssa.uk.net). Arthritis 
Research UK (www.arthritisresearchuk.org) provides helpful information and leaflets on 
Sjögren’s syndrome, anti-rheumatic drugs and life-style advice. 
 
Recommendations for Non-pharmacological interventions for systemic disease 
I. Regular exercise and, where appropriate, a graded exercise programme, are 
recommended for patients with Sjögren’s syndrome presenting with fatigue. Level of 
evidence IIb/B; SOA 9.33 (93.3%) 
II. Provide written patient information and details of appropriate support groups and 
on-line resources. Level of evidence IV/D; SOA 9.8 (100%) 
 
Immunomodulation for systemic disease 
Early and aggressive immunomodulation is recommended for rheumatoid arthritis and 
increasingly for other autoimmune diseases but not well established for Sjögren’s 
syndrome. An evidence base is lacking and patients with Sjögren’s syndrome often tolerate 
these drugs poorly. There is however increasing insight into the pathogenesis of Sjögren’s 
syndrome and interest in its therapeutic management with an increase in the use of 
conventional disease modifying drugs and research interest in the development of targeted 
biological agents. The guideline working group considered the evidence supporting the use 
of corticosteroids, disease modifying drugs, biologics and other drugs alongside their own 
experience. Where disease modifying drugs are used they should be monitored in 
accordance with the recommendations of the latest BSR DMARD guidelines (in press). 
Biologics are not currently NICE approved or funded for the treatment of Sjögren’s 
syndrome.  
Systemic pulmonary manifestations of sjogren’s include Interstitial Lung Disease (ILD) and 
cysts. Usual Interstitial Pneumonitis (UIP) and Non Specific Interstitial Pneumonitis (NSIP) 
are the most commonly reported.  In general systemic steroids are recommended as first 
line treatment, then subsequently various immunosuppressives, including 
cyclophosphamide and azathioprine, rituximab and anti-malarials depending on steroid 
responsiveness  (128-130). A broad range of neurological complications have been 
described in Sjögren’s. A diffuse sensorimotor neuropathy, confirmed on nerve conduction 
testing, may affect more than 15% of patients with Sjögren’s (131). There are anecdotal 
reports of benefit from rituximab, immunoglobulins, azathioprine and hydroxychloroquine 
(131). 
Trigeminal Neuropathy/Neuralgia has been described in up to 5% of patients with Sjögren’s. 
It does not usually respond to treatment with steroids and in general is treated as for 
trigeminal neuralgia of unknown cause. Mononeuritis multiplex is probably seen in less than 
3% of Sjögren’s patients over their lifetime. It is associated with vascultis and may respond 
to treatment with steroids and cyclophosphamide (132). Autonomic neuropathy is common 
and correlates with patient reported outcomes (133). It may respond to simple, 
symptomatic treatment. Sjögren’s syndrome myelopathy can mimic Multiple Sclerosis. 
Patients may present with paraplegia, sensory changes and bladder dysfunction.  Steroids 
and cyclophosphamide may be helpful (134).  
Signal hyperintensities on Brain MRI have been described in patients with Sjögren’s and 
have been postulated to indicate the presence of an underlying cerebral vasculopathy (135). 
Correlation with serological abnormalities and clinical symptoms is poor however. 
Neuromyelitis Optica Spectrum disorder is associated with the presence of aquaporin-4 
antibodies and although seen in association with Sjögren’s may not be a direct neurological 
complication of Sjögren’s. This patient group benefits from aggressive and ongoing 
immunosuppression (136). 
 
Although significant renal impairment is rare Tubulointerstitial nephritis or more rarely, 
immune complex glomerulonephritis, are well described renal manifestations of Sjögren’s. 
In those patients with Tubulointerstitial nephritis there is a mononuclear lymphocytic 
infiltrate on renal biopsy and treatment with mycophenolate and steroids improves the 
renal function (137). 
 
Corticosteroids 
Prednisolone has been shown to help systemic features including lung disease (128-130) 
cytopaenias (138), and, in combination with cyclophosphamide or chlorambucil, 
neurological involvement (139, 140). Small studies of low dose prednisolone (5-7.5mg per 
day) have shown improvements in sicca symptoms and modest improvements in salivary 
flow (141).  
There are no controlled trials of pulsed IV methylprednisolone or IM depomedrone in 
Sjögren’s although there are anecdotal reports of successful use of pulsed steroids in 
patients with Sjögren’s associated lung disease (142), ganglionopathy (143), myelopathy 
(134) and renal involvement (144). 
 
Recommendations for Corticosteroids 
I. Corticosteroids are not recommended for the routine treatment of primary Sjögren’s 
syndrome although intermittent short courses of oral or intramuscular steroid are 
effective for systemic flares of disease and steroids may be used for significant organ 
manifestations with or without additional immunosuppressive treatment. Level of 
evidence III/C; SOA 9.2 (100%) 
II. Low dose oral prednisolone is effective in treating persistent constitutional 
symptoms in patients who have failed to respond to Hydroxychloroquine or other 
immunosuppresants. Level of evidence IIb/B; SOA 8.92 (100%) 
 
Recommended DMARDS 
Hydroxychloroquine 
Evidence of efficacy of hydroxychloroquine in Sjögren’s syndrome is variable. A number of 
studies (145-148) suggest modest improvements in ocular and oral dryness, lowering of 
erythrocyte sedimentation rate (ESR) and immunoglobulin levels, together with reductions 
in fatigue levels and joint pain in patients treated with Hydroxychloroquine.  
The JOQUER study, an RCT of Hydroxychloroquine 400mg daily, which studied a group with 
mild disease (i.e no systemic disease), failed to reach its primary outcome of a 30% 
improvement in 2 out of 3 outcomes (VAS of pain, dryness, fatigue) at six months but it did 
confirm a decrease in immunoglobulin levels and ESR in treated patients. The study was 
extended to 48 weeks with all patients being prescribed Hydroxychloroquine between 
weeks 24 and 48.  Although there was a suggestion of clinical and serological improvement 
in the cohort taking a full 12 months of hydroxychloroquine in the open-label extension this 
did not reach statistical significance (149).  
A meta-analysis of 6 earlier trials involving 140 female patients failed to identify a clear 
benefit of antimalarials but commented that the available evidence was of poor quality and 
called for more and better quality research (150). 
All members of the Guideline working group recommended a therapeutic trial of 
Hydroxychloroquine treatment in patients with evidence of systemic disease starting at 
400mg once daily decreasing after 6 weeks to 200mg once daily with monitoring as per BSR 
guidelines. 
 
Recommendations for Hydroxychloroquine 
I. Hydroxychloroquine up to a maximum dose of 6mg/kg is recommended for patients 
with Primary Sjögren’s Syndrome especially those with skin and joint disease and 
fatigue. Patients should be monitored for evidence of a clinical and/or biological 
response (e.g. falling Immunoglobulin levels). If no response after 12 months of 
treatment consider stopping. Level of evidence IIa/B; SOA 9.64 (100%) 
 
Azathioprine 
Azathioprine has been reported as helpful in case reports for systemic complications such as 
lung disease (151), myelopathy (152) and cytopaenias (153) but a double blind placebo 
controlled trial in a small cohort of patients with uncomplicated disease suggested that it 
did not have a routine role in treatment and was associated with a high frequency of side 
effects (154). There is however some evidence for efficacy of azathioprine in both UIP and 
NSIP, the most commonly reported forms of interstitial lung disease in Sjögren’s (129, 130, 
155, 156). Discontinuation rates of azathioprine due to non-respiratory side effects may be 
higher than for Mycophenolate although efficacy is similar in patients with interstitial lung 
disease (157). 
 
Recommendations for Azathioprine 
I. Azathioprine is not routinely recommended for management of uncomplicated 
Sjögren’s but may be considered in patients with systemic complications e.g. lung 
disease, myelopathy and cytopaenias. Level of evidence III/C; SOA 9.09 (100%) 
 
Methotrexate 
Methotrexate is the drug of choice for patients with significant inflammatory arthritis (158). 
There are case reports of successful treatment of Sjögren’s associated inclusion body 
myositis (159) and myelopathy (160) with methotrexate. An open label, pilot study of 
weekly methotrexate in 17 patients showed improvement in sicca symptoms, parotid 
swelling, dry cough and purpura but no improvement in objective parameters of dry eyes 
and mouth (161).  
 
Recommendations for Methotrexate 
I. Methotrexate may be useful for those patients with an associated inflammatory 
arthritis but there is not enough evidence for its routine use as a disease-modifying 
drug for those with sicca symptoms alone. Level of evidence IV/D SOA 9.54 (100%) 
 
Mycophenolate 
A single center, open-label pilot trial of mycophenolate in 11 patients reported subjective 
improvement of ocular dryness and reduction in artificial tear use, but objective evidence of 
significant glandular improvement in only two patients with short disease duration. There 
was significant reduction in hypergammaglobulinemia and rheumatoid factor levels and 
increase in complements and white cell levels (162). A case report (163) documents 
successful treatment of refractory agranulocytosis with mycophenolate in a patient with 
primary Sjögren’s. There is emerging evidence supporting the use of mycophenolate in 
patients with CTD related interstitial lung disease including Sjögren’s  syndrome (164, 165). 
Mycophenolate has been show to stabilise Scleroderma associated Interstitial lung disease 
in a randomized controlled trial (166). There are to date no similarly robust clinical trials 
supporting mycophenolate in Sjögren’s associated interstitial lung disease but there are 
anecodatal reports and small case series suggesting benefit (167, 168). 
  
Recommendations for Mycophenolate 
I. The use of mycophenolate may be considered in patients with systemic 
complications such as cytopaenias or lung disease. Level of evidence III/C; SOA 9.1 
(100%) 
 
Ciclosporin A 
There are anecdotal reports of successful treatment of Sjögren’s associated interstitial 
cystitis (169), annular erythema (170, 171), red cell aplasia (172) and pneumonitis (173) with 
oral cyclosporine. An open-label phase II study of low dose Ciclosporin A (2mg/kg) showed 
reductions in joint swelling and tenderness, a fall in the EULAR Sjögren's Syndrome Disease 
Activity Index (ESSDAI) and Hospital Anxiety Questionnaire (HAQ) and improvements in both 
the physical and mental health domains of the Short Form 36 (SF36) (174). 
 
Recommendations for Ciclosporin A 
I. Ciclosporin A is not routinely recommended for management of uncomplicated 
Sjögren’s although it may be helpful in patients with significant joint involvement 
Level of evidence III/C; SOA 8.58 (85.7%) 
 
Cyclophosphamide 
There are no controlled trials of cyclophosphamide in Sjögren’s syndrome and in general its 
potential toxicity would preclude routine use. However there are published case reports and 
series  documenting successful treatment of Sjögren’s associated myelopathy (134, 139) 
with pulsed monthly cylclophosphamide , refractory thrombocytopaenia (175) with pulsed 
followed by oral cyclophosphamide, glomerulonephritis (144, 176) with both pulsed and 
oral cyclophosphamide and lung disease (177) with pulsed intravenous cyclophosphamide.  
 
Recommendations for Cyclophosphamide 
I. The use of cyclophosphamide (usually in combination with steroids) may be 
considered in patients with organ threatening systemic complications such as central 
nervous system, renal or lung disease.  Level of evidence III/C; SOA 9.09 (100%) 
 
DMARDS not routinely recommended 
Leflunomide 
Two phase II open label pilot studies found very modest benefits and multiple side effects 
(178, 179).  
 
Recommendations for Leflunomide 
I. Leflunomide is not routinely recommended for Primary Sjögren’s Syndrome. Level of 
evidence III/C; SOA 9.8 (100%) 
 
Penicillamine 
A prospective open label study found very modest benefits and multiple side effects (180).  
 
Recommendations for Penicillamine 
I. Penicillamine is not routinely recommended for Primary Sjögren’s Syndrome. Level 
of evidence III/C; SOA 10 (100%) 
 
Biologics for systemic disease 
Rituximab  
There is accumulating evidence from published case studies and case series supporting the 
use of rituximab in patients with active, systemic primary Sjögren’s syndrome.  
Rituximab has evidence of efficacy from small case series and case reports in the treatment 
of Sjögren’s related lymphoma, immune thrombocytopaenia, cryoglobulinaemia and 
neurological disease (181-191). 
A number of open label studies and RCTs have looked at the effect of rituximab on the 
fatigue and sicca manifestations (see appendix 3 for a summary). An open label study of 12 
patients (192) observed modest improvements in patient reported fatigue and oral dryness 
at 26 weeks following a single treatment course of rituximab. The TEARS study (193) found 
no significant differences between treatment and placebo arms in the primary end point (an 
improvement of at least 30mm in 2 of 4 VAS scores at week 24 following a single treatment 
course of rituximab). However there was a significant improvement in the fatigue VAS 
scores in the treatment group at 6 weeks and 16 weeks.  The multicentre UK based 
TRACTISS trial (194) has recently been completed. Although preliminary analysis has shown 
no consistent benefit on fatigue, dryness and salivary flow further analysis of data is being 
conducted. A recent study has suggested that patients with higher levels of B cell infiltration 
within the parotid glands are more likely to respond to rituximab suggesting that we may in 
future be able to target therapy more effectively (195). There is evidence that B cell 
activating factor (BAFF) is upregulated after rituximab treatment (196) and this may explain 
the observation in the TEARS study that patients had improved at 4 months but 
deteriorated again by 6 months (193).  
The dose, duration between doses and treatment response in the smaller studies and case 
series is listed in Appendix 3 but in the TEARS study (193) patients received just two 1g 
pulses of Rituximab 2 weeks apart at baseline, whereas in the TRACTISS study (194) this was 
repeated at six months. 
In conclusion there is currently insufficient evidence to recommend routine use of rituximab 
in those with predominantly fatigue and sicca manifestations but good evidence for its use 
in systemic complications and lymphoma. Use of Rituximab in primary Sjögren’s syndrome is 
not currently NICE approved and is not routinely funded for the treatment of Sjögren’s 
syndrome with the exception of those patients presenting with lymphoma. 
 
Recommendations for Rituximab 
I. Rituximab is recommended for specialist use in patients with significant systemic 
manifestations refractory to treatment with steroids and other immunosuppressives. 
It has a role in those with lymphoma, Immune thrombocytopaenia, vasculitic 
neuropathy and cryoglobulinaemias. Level of evidence IIb/B; SOA 9.43 (100%) 
 
Biologics where more evidence of efficacy is required 
Belimumab 
Belimumab is a human monoclonal antibody that inhibits B-cell activating factor (BAFF). An 
open-label study of Belimumab, in 30 patients with primary Sjögren’s syndrome 
demonstrated a significant improvement in the ESSDAI score from baseline with particular 
improvement in non-malignant glandular swelling (197). Although not currently routinely 
used in Sjögren’s syndrome belimumab has also been reported to be of benefit in case 
reports in combination with rituximab (198) and further trials of belimumab, including a 
combined study with rituximab, are currently underway. 
 
Recommendations for Belimumab 
I. Belimumab is not currently recommended although it merits further study. Level of 
evidence IIb/B; SOA 9.46 (92.8%) 
 
Abatacept 
Abatacept was well tolerated in one open label pilot study and fatigue and health related 
quality of life improved significantly over a 24 week treatment period (199). There is a Phase 
II study currently underway (https://clinicaltrials.gov/ct2/show/NCT02067910). 
 
Recommendations for Abatacept 
I. Abatacept is not currently recommended although it merits further study. Level of 
evidence III/C; SOA 9.46 (92.8%) 
 
Biologics not currently recommended 
Anti-TNF therapy 
Initial open label studies of anti-TNF agents suggested some benefit (200-202) but 
subsequent randomised double-blind controlled trials have failed to show clinical or 
serological improvement in patients with Sjögren’s following treatment with anti-TNF in the 
form of etanercept (203) or infliximab (204).  
 
Recommendations for Anti-TNF therapy 
I. Anti-TNF therapies are not recommended for treatment of Primary Sjögren’s 
Syndrome Level of evidence Ib/A; SOA 9.38 (85.7%) 
 
IFN alpha 
IFN alpha therapy via the oro-mucosal route is not currently available in the UK for the 
treatment of Sjögren’s syndrome although there is some evidence of efficacy with moderate 
improvements in unstimulated salivary flow rates in phase II and III studies (205-208).  
 
Recommendations for IFN alpha 
I. IFN alpha therapy via the oro-mucosal route is not currently recommended for the 
treatment of Sjögren’s syndrome. Level of evidence Ib/B;  SOA  
 
Anti-IL1 (Anakinra) 
A double-blind, placebo-controlled parallel group study (209) of anakinra in primary 
Sjögren’s syndrome failed to reach its primary end-point although more patients on the 
active drug than on placebo reported a 50% reduction in fatigue.  
 
Recommendations for Anti-IL1 
I. Anakinra (an anti-IL-1 receptor antagonist) is not recommended for the treatment of 
Primary Sjögren’s Syndrome. Level of evidence Ib/A; SOA 9.82 (100%) 
 
Tociluzimab 
Tocilizumab, an anti-interleukin-6 receptor antibody, is used routinely in the treatment of 
patients with Rheumatoid Arthritis but is not licensed for use in Sjögren’s syndrome. A 
single case report describes successful treatment of refractory organising pneumonia 
associated with Sjögren's (210) but there is insufficient evidence to recommend its use 
pending further studies. 
 
Recommendations for Tociluzimab  
I. Tociluzimab (an anti-IL-6 receptor antibody) is not recommended for the treatment 
of Primary Sjögren’s Syndrome. Level of evidence III/C; SOA 9.82 (100%) 
 
Efalizumab 
A small, open label study of 3 patients showed no clinical improvement and a significant 
increase in inflammation on minor salivary gland biopsy with the development of new anti-
dsDNA antibodies in 2 of the 3 subjects (211).  
 
Recommendations for Efalizumab 
I. Efalizumab is not recommended for the treatment of Primary Sjögren’s Syndrome. 
Level of evidence III/C 
 
Other Potential Treatments for Systemic Disease 
Intravenous Immunoglobulins 
There is evidence supporting the use of immunoglobulin therapy in Sjögren’s associated 
sensorimotor and non-ataxic sensory neuropathy from retrospective & observational 
cohorts & case reports (212, 213). Immunoglobulin treatment has also been used 
successfully in refractory Sjögren’s associated myositis not responding to conventional 
treatment (214). There is no evidence for its routine use in patients without significant 
complications. 
 
Recommendations for Intravenous Immunoglobulins 
I. Immunoglobulin treatment is not routinely used in primary Sjögren’s syndrome 
although it may be effective in Sjögren’s associated myositis and neuropathies and 
its use in these conditions may be justified if the patient has failed to respond to 
treatment with steroids and conventional immunosuppression. Level of evidence 
III/C; SOA 9.43 (100%) 
 
Colchicine 
There are case reports describing successful treatment of Sjögren’s  associated 
hypergammaglobulinaemic purpura (215), Granulomatous Panniculitis (216) and pericarditis 
(217) with colchicine. 
 
Recommendations for Colchicine 
I. Colchicine may be considered as adjunctive treatment in patients with cutaneous 
manifestations or pericarditis not responding to hydroxychloroquine or other 
treatments. Level of evidence III/C; SOA 8.45 (85.7%) 
 
Dapsone 
There are case reports describing successful treatment of Sjögren’s associated subacute 
cutaneous lupus erythematosus and urticarial vasculitis (218), Pyoderma gangrenosum 
(219) and cutaneous vasculitis (220) with dapsone.  
 
Recommendations for Dapsone 
I. Dapsone may be considered as adjunctive treatment in patients with cutaneous 
manifestations not responding to hydroxychloroquine. Level of evidence III/C; SOA 
8.8 (100%) 
 
Topical Tacrolimus 
There are case reports describing successful treatment of annular erythema associated with 
Sjögren’s syndrome (221) with Topical Tacrolimus. Studies of tacrolimus suggest an 
increased incidence of skin cancer so it should be used sparingly for a limited amount of 
time. 
 
Recommendations for Tacrolimus 
I. Topical Tacrolimus may be considered as adjunctive treatment in patients with 
cutaneous manifestations not responding to hydroxychloroquine. Level of evidence 
III/C; SOA 8.75 (100%) 
 
Other drugs not recommended 
Dehydroepiandrosterone (DHEA) substitution treatment  
Two double-blinded, randomised studies of DHEA treatment in Sjögren’s syndrome failed to 
show any symptomatic improvement or changes in clinical or serological measures in 
treated patients compared to placebo (222, 223). 
 
Recommendations for Dehydroepiandrosterone 
I. Dehydroepiandrosterone (DHEA) substitution treatment is not recommended in 
Primary Sjögren’s Syndrome. Level of evidence Ib/A; SOA 9.45 (100%) 
 
Management of Pregnancy 
Fertility is normal in patients with Primary Sjögren’s syndrome although there is an 
increased risk of recurrent miscarriage in the Ro/La + group (224-226). Neonatal lupus rash 
occurs in about 5% of live births in Ro/La positive women usually appearing at 6 weeks of 
age and lasting about 17 weeks before fading and clearing completely. A few children have 
persistent depigmentation or telangiectasia (227). Congenital heart block (CHB) occurs in 
less than 2% of pregnancies in women with anti Ro or La antibodies and may be detected by 
ultrasound scanning from about 16 weeks gestation (228). There is evidence that in anti-Ro 
positive women, foetal atrioventricular (AV) time intervals are longer and heart rates slightly 
lower compared with controls. Foetuses with normal AV time intervals at 18-24 weeks had 
normal electrocardiographic results at birth. Hence serial Doppler echocardiographic 
measurement of AV time intervals is suggested as a useful method for surveillance of these 
high-risk pregnancies (229). Following an affected pregnancy the risk of CHB goes up to 17% 
for subsequent pregnancies. 70% of affected children survive but nearly all require 
pacemakers in the first few months of life (230). There is some evidence from longitudinal, 
observational studies that Primary Sjögren’s syndrome mothers deliver significantly earlier, 
give birth to babies with lower birth weight and have complications during deliveries more 
frequently than women in the general population (226). Other, very rare, complications 
include hepatitis and cytopenias affecting the newborn. Only a handful of cases have been 
reported in the literature and in the majority of cases the child has improved spontaneously 
(231). 
Successful pregnancies are however, increasingly common in patients with Sjögren’s. There 
is evidence that low-dose aspirin initiated in early pregnancy improves placental 
implantation and reduces the incidence of both pre-eclampsia and intra-uterine growth 
retardation (232, 233). The working group therefore recommended that in Sjögren’s 
pregnancy one should consider low dose aspirin to improve placental implantation and 
monitor closely with serial US. It is safe to continue hydroxychloroquine throughout 
pregnancy with evidence in patients with Systemic Lupus Erythematosus of improved 
outcomes for the mother and no detrimental effects on the child (234-237). Refer to the 
BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding (236, 237). 
 
Recommendations for Management of Pregnancy 
I. Consider low dose aspirin to improve placental implantation Level of evidence IIb/B; 
SOA 8.27 (92.8%) 
II. Monitor closely with serial US if anti Ro and/or La positive and consider referral to 
specialist centre Level of evidence IIb/B; SOA 9.71 (100%) 
III. Review all medication in pregnancy. Hydroxychloroquine may be continued 
throughout pregnancy and breastfeeding Level of evidence I/A; SOA 7.91 (85.7%) 
 
Assessment of Lymphoma Risk 
The risk of lymphoma development in patients with Primary Sjögren’s syndrome increases 
from 3% in the first 5 years to 9.8% at 15 years i.e. up to 40 times the population risk (238-
240). The presence of lymphadenopathy, parotid enlargement, palpable purpura, low serum 
C4 levels and cryoglobulins are the most consistent predictors of future risk (241) and may 
increase the risk of future development of lymphoma up to five fold (239). The detection of 
Germinal Centre-like structures or a focus score >3 on light microscopy in diagnostic salivary 
gland biopsies from patients with Primary Sjögren’s syndrome may suggest a future higher 
risk for lymphoma development (242). The majority of lymphomas are of the Mucosa-
associated lymphoid tissue (MALT) type. The median age of onset is mid-50’s and the 
diagnosis of Sjögren’s generally pre-dates the lymphoma by a mean of 7 years (238). 
Commonest sites of presentation include the parotid and other salivary glands, followed by 
the orbits, stomach, thyroid, lung, upper airways, and rarely other sites (243). Presentation 
is usually with a firm, palpable swelling within the gland. GI tract lymphoma may present 
with chronic diarrhoea, malabsorption and weight loss (244).  
  
Recommendations for Assessment of Lymphoma Risk 
I. Review high risk patients regularly and warn patients to report firm, painless 
glandular swelling that doesn’t settle Level of evidence IV/D; SOA 9.86 (100%) 
 
Management of Lymphoma 
Ultrasound allows assessment of any new swelling within the major salivary glands and, 
used in conjunction with Doppler signals, may help differentiate between benign and 
malignant lesions. (112).  
Biopsy is usually necessary to confirm the diagnosis. CT scanning is helpful for staging. 
Treatment can be variable and may include a ‘watch and wait’ approach in patients with 
localized low-grade lymphoma or radiation alone but is generally with surgical excision 
followed by radiotherapy, chemotherapy, generally including rituximab, or a combination of 
the two. There are regularly updated UK guidelines available.The prognosis is generally good 
with a complete response to initial treatment in >90% and 5 year disease free survival >75% 
(243) but splenomegaly, low serum C3, levels, neutropaenia and lymphopaenia may indicate 
a higher risk of poor outcome (241).  Refer to haematology/oncology for detailed advice on 
management.   
 
Recommendations for Management of Lymphoma 
I. Investigate suspicious lesions with local US, biopsy and CT chest, abdomen and pelvis 
for staging Level of evidence III/C; SOA9.77 (100%) 
 
Conclusion 
Primary Sjögren’s syndrome is a chronic, debilitating condition that warrants effective 
management. All patients should be counselled and offered topical management for sicca 
symptoms. Systemic treatment should be considered early in those with constitutional 
symptoms.  
Applicability and Utility 
Key standards of care and potential organisational barriers to implementation 
Primary Sjögren’s syndrome is associated with significant direct and indirect costs and 
represents a significant impact on the healthcare system(245, 246). The initial management 
of Sjögren’s syndrome includes educating the patient on appropriate management and 
initiating simple treatments such as moisturising eye drops and fluorinated mouth gels. This 
is best done by a physician with an interest and some background knowledge. Patients also 
benefit from the additional time and expertise of an appropriately trained specialist nurse. A 
baseline ophthalmic and oral medicine specialist assessment, are recommended. 
Appropriate, early management will improve outcomes for patients and prevent the 
development of excess dental caries and potentially reduce the future health care needs of 
these patients. A multi-disciplinary clinic setting has been shown by one specialist unit to 
provide a cost effective and high quality environment for patient care whilst facilitating 
involvement in research (247)  
 
Mechanism for audit of the guideline 
An audit pro forma to assess compliance with these guidelines is available on the BSR 
website. 
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Appendix 1  
 
Search History 
1. Medline; (primary AND jsogren*).ti,ab; 0 results. 
2. Medline; jsogren*.ti,ab; 0 results. 
3. Medline; (primary AND sjogren*).ti,ab; 4103 results. 
4. Medline; (primary adj3 sjogren*).ti,ab; 3183 results. 
5. Medline; exp SJOGREN'S SYNDROME/; 10593 results. 
6. Medline; 3 OR 4 OR 5; 11390 results. 
7. Medline; exp THERAPEUTICS/; 4717602 results. 
8. Medline; (treatment* OR therap*).ti,ab; 4362809 results. 
9. Medline; 7 OR 8; 7552870 results. 
10. Medline; 6 AND 9; 3071 results. 
11. Medline; 10 [Limit to: Publication Year 1990-2015]; 2605 results. 
 
Level of evidence 
Ia From meta-analysis of randomized controlled trials (RCTs) 
Ib From at least one RCT 
IIa From at least one controlled study without randomization 
IIb From at least one type of quasi-experimental study 
III From descriptive studies such as comparative studies, correlation studies of case-
control studies 
IV From expert committee reports or opinions and/or clinical experience of respected 
authorities 
 
Determination of recommendation strength 
A Category 1 evidence 
B Category 2 evidence or extrapolated recommendations from category 1 evidence 
C Category 3 evidence or extrapolated recommendations from category 1 or 2 
evidence 
D Category 4 evidence or extrapolated recommendations from category 2 or 3 
evidence 
 
Appendix 2: Dry mouth products available in the UK 
 Fluoride containing 
& pH neutral 
Non-fluoride 
Oral Gels Biotène 
Oralbalance® 
BioXtra® 
Oralieve® 
Xerostom® 
 
Oral spray AS Saliva Orthana® 
Xerostom 
Aequasyal® (pH neutral) 
Glandosane®(pH acidic) 
Saliveze®(pH neutral) 
Xerotin®(pH neutral) 
Lozenges AS Saliva Orthana® 
Xerostom 
Salivix® (pH acidic) 
SST (pH acidic) 
Toothpastes Duraphat® 2800 ppm 
Duraphat® 5000 ppm 
 
Mouth washes  Biotène Dry Mouth Oral 
Rinse® (pH balanced) 
BioXtra Mouth wash® 
Xerostom® 
 
  
Appendix 3 - Rituximab summary table 
Study Design Dose Outcome 
Measured 
Results Ref 
Pilot Study of 17 
patients with PSS in a 6-
month double-blind 
randomized controlled 
pilot study 
 
Rituximab 1000mg 
at time 0 and 15 
days versus 
placebo 
Fatigue This study showed a significant 
improvement in the fatigue visual 
analogue scale (VAS) between 
baseline and 6 months (mean 
improvement 36.8 (SD 17.8) 
p<0.001) in patients who received 
active therapy (Figures 1 & 2 
below). 
(1) 
A double-blind 
randomised controlled 
study of 30 PSS patients 
Rituximab 1000mg 
x 2 (20 patients) 
versus placebo (10 
patients 
Salivary flow 
and oral 
dryness 
The active group showed significant 
improvement in salivary flow and 
oral dryness VAS at 6 months 
(2) 
Open-label study of 16 
PSS patients  
Rituximab 
375mg/m2 x2 
treatments one-
week apart 
(without 
corticosteroids) 
Fatigue 
Dryness 
Pain 
Treated patients showed 
improvement in fatigue, pain, 
dryness, patient global VAS and SF-
36 scores 
(3) 
Open – label study of 
15 PSS patients, 7 of 
whom also had MALT 
lymphoma 
Rituximab 
375mg/m2 x4  
weekly infusions 
Dryness and 
Stimulated 
salivary flow 
Patients showed significant 
improvement of subjective dryness 
symptoms and increase in 
stimulated salivary flow was 
observed in patients with residual 
salivary gland function. Three of the 
8 patients with PSS without MALT 
lymphoma had a serum sickness-
like disorder. 
 
(4) 
A retrospective study of 
16 PSS patients with 
severe systemic 
features (lymphoma 
n=5, polyarthritis n=4, 
cryoglobulinaemia n=5, 
thrombocytopaenia 
n=1, mononeuritis 
multiplex n=1) 
Rituximab:  
14 patients 
received 
375mg/m2  x4 
weekly infusions  
1 patient received 
375mg/m2 x6 
weekly infusions 
I patient received 
1000mg x2 weekly 
infusions 
Dryness Improvement was observed in 4 
out of 5 patients with lymphoma 
and 9 of 11 with systemic 
involvement. Dryness was 
improved in a minority of patients 
(but it is not clear how many 
patients had residual gland 
function). Only one patient had a 
serum sickness-like reaction. 
(5) 
Open label study of 12 
patients with PSS 
Rituximab 1g given 
at day 1 and 15 
Safety. Modest improvements were 
observed at week 26 in patient-
reported symptoms of fatigue and 
(6) 
oral dryness, with no significant 
improvement in the objective 
measures of lacrimal and salivary 
gland function. 
Open label study of 78 
patients. Systemic 
disease in 74 (eg 
articular, vasculitis, 
neurological, renal) and 
salivary gland swelling 
in 4. 
Rituximab 1g x 2 in 
67 and 375mg/m2 
x 4 in 11 
ESSDAI  Overall efficacy according to the 
treating physician was observed in 
47 patients (60%) after the first 
cycle of rituximab. Median ESSDAI 
decreased from 11 (2–31) to 7.5 (0–
26) (p<0.0001). Median dosage of 
corticosteroid decreased from 17.6 
mg/day (3–60) to 10.8 mg/day 
(p=0.1). 
(7) 
4 patients with PSS and 
thrombocytopenia 
Weekly rituximab 
100mg and 
prednisolone 
Platelet 
count 
Platelets rose from <40 to >100 and 
remained for >6 months 
(8) 
20 patients with PSS in 
an RCT for 12 months 
Rituximab 1g given 
at day 1 and 15 
ESSDAI Significant reduction in ESSDAI from 
8 to 6 in Rituximab treated group 
(9) 
28 patients with PSS 
treated with rituximab 
Rituximab 1g given 
at day 1 and 15 
ESSPRI & 
ESSDAI 
Median (range) ESSPRI and ESSDAI 
scores at baseline were 6.7 (0.3-9.0) 
and 8 (2-18), respectively. Both 
indices improved significantly after 
treatment.  
(10) 
13 patients with PSS 
and cryoglobulinaemic 
vasculitis and 17 with 
PSS and MALT 
lymphoma 
Rituximab 500mg 
weekly +/- 
cyclophosphamide 
Remission of 
Vasculitis 
&/or MALT 
lymphoma 
Rituximab monotherapy led to 88% 
clinical remission in vasculitis &/or 
MALT lymphoma. With 
cyclophosphamide 100% remission 
(11) 
Observational study of 
53 patients with PSS 
developing non-
Hodgkins lymphoma 
(NHL) 
Various regimes 
including CHOP 
chemotherapy with 
Rituximab (CHOP-
R) 
Remission of 
NHL 
Diffuse large B-cell lymphomas 
treated with CHOP-R had a 100% 3-
year survival. Mucosa associated 
lymphoid tissue (MALT) lymphomas 
treated with chemotherapy and/or 
rituximab had a 97% 3-year survival 
rate 
(12) 
Observational study of 
17 patients with 
neurological 
involvement 
Various rituximab 
regimes 
Clinical 
remission. 
Reduction in 
Rankin and 
ESSDAI 
scores 
In 9/10 patients with 
cryoglobulinaemia/vasculitis the 
neurological features improved and 
in 2/7 without 
cryoglobulinaemia/vascilitis. Rankin 
scores fell from 3 to 2 by 3 months 
(p<0.02) and ESSDAI from 18 to 11 
(p<0.05) 
(13) 
Retrospective Rituximab Clinical Of 13 patients treated with (14) 
observational study of 
35 patients with PSS 
and MALT Lymphoma 
375mg/m2x4 or 
with 
cyclophosphamide 
eg 375mg/m2 
every 3-4 weeks x 
6-8 occasions 
remission of 
lymphoma 
rituximab 5 went into complete 
remission and 8 into partial 
remission or stable disease. Of 6 
patients treated with 
chemotherapy + rituximab all 6 
went into complete remission 
Case report. 47 year old 
female with 
progressive lower limb 
weakness unresponsive 
to cyclophosphamide 
Rituximab 
375mg/m2 x 4 
Clinical 
improvement 
of 
neuropathy 
Patient improved clinically, able to 
walk for 60 meters. Improvement 
maintained at 8 months post 
treatment 
(15) 
Case series of 4 
patients with IVIG 
dependent chronic 
idiopathic 
demyelinating 
polyneuropathy (CDIP. 
One of whom had SS 
Rituximab 
375mg/m2 x 4 
Reduction in 
IVIG usage by 
at least 
25%/year 
and clinical 
measures in 
CDIP 
The patient with SS had >25% 
reduction in IVIG usage 
(16) 
Case report of a patient 
with SS and 
autoimmune 
pancreatitis  
Rituximab Clinical 
improvement 
of 
pancreatitis 
Case report. Multiple admissions 
despite prednisolone therapy. 
Avoided hospital post rituximab 
(17) 
Patient with coeliac 
disease and pSS 
Riuximab 1g x 2 at 
baseline followed 
by 1g at 6/12 
intervals 
Serology 
(antiTTG, 
IgG’s, C3/4 
levels), 
PROMS 
Significant improvement in GI, 
constitutional, functional & 
serological meansures of disease 
activity at 12/12 
(18) 
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